Sorrento Therapeutics Inc (SRNE): Dawson James has a $16 price target for...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	57
Posts	5700
Boards Moderated	0
Alias Born	12/13/2004

dia76ca

Re: None

Tuesday, 03/15/2022 11:46:50 AM

Tuesday, March 15, 2022 11:46:50 AM

Dawson James has a $16 price target for Sorrento. That is based in part on its assumption of a 70% probability of success of its therapies. But the amazing part is in exhibit 1, its revenue model, it ascribed ZERO (0) revenue to any therapy in 2022! Sorrento already has some COVISTIX revenue in Q1 of 2022, with a lot more to come as production ramps up. And there are several other Covid products(eg.COVI-MSC) which could produce significant revenue in 2022. Most of us would be pleased with $16 a share this year, but the chances are that the share price would far exceed that if the analysis actually included revenue WE ALREADY KNOW HAS BEEN ACHIEVED!

"The refusal of the real is the number one dogma of our time" Rene Girard

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent SRNE News

Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM